Bioengineered small extracellular vesicles (sEV) as new cancer immunotherapies to counteract immune suppression

sEVs represent a complex cell communication system that contributes to immune suppression in cancer through inhibitory immune checkpoint (IC) ligands at their surface. Here we will produce bioengineered sEVs displaying IC receptors acting as scavenger to counteract tumour-derived sEVs within the TME. Engineered sEVs with different combinations of IC receptors will be produced from stromal cells. Functionalities and efficacy of these sEVs will be investigated in advanced preclinical models using CyTOF, imaging flow cytometry and high-resolution microscopy.